Why the study?
Does a novel europium nanoparticle-based immunoassay (ENIA) accurately detect influenza A and B viruses in clinical samples compared to RT-PCR?
Does a novel europium nanoparticle-based immunoassay (ENIA) accurately detect influenza A and B viruses in clinical samples compared to RT-PCR?
A novel europium nanoparticle-based immunoassay provides rapid and sensitive detection of influenza A and B viruses in clinical samples.
May support rapid influenza testing; leaves open prospective validation before clinical adoption.
We report the development of a novel europium nanoparticle-based immunoassay (ENIA) for rapid detection of influenza A and influenza B viruses. The ENIA demonstrated sensitivities of 90.7% (147/162) for influenza A viruses and 81.80% (9/11) for influenza B viruses compared to those for an in-house reverse transcription (RT)-PCR assay in testing of influenza-positive clinical samples.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: